SCHEMBL10427993

SCHEMBL10427993

CCCCCCCCCCCCNC(=O)[C@@H](N)[C@@H](C)O

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.59
RRM1 P23921 1/20 0.58
GNAI3 P08754 1/20 0.55
GNAO1 P09471 1/20 0.55
GNAI1 P63096 1/20 0.55
EPHX1 P07099 6/20 0.52
MMP8 P22894 1/20 0.51
SPHK1 Q9NYA1 4/20 0.51
S1PR2 O95136 2/20 0.51
S1PR1 P21453 2/20 0.51
S1PR3 Q99500 2/20 0.51
S1PR5 Q9H228 1/20 0.51
NAAA Q02083 2/20 0.50
METAP2 P50579 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15659209 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15660958 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15659192 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15657338 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15658610 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15661217 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15662158 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL16414566 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15660830 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1
SCHEMBL15657340 1.00 DPP7 (0.59) DPP7RRM1GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031892-A1 SPHINGOLIPID METABOLITE MIMETICS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-01-29 US disclosed
US-20150031892-A1 SPHINGOLIPID METABOLITE MIMETICS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-01-29 US disclosed
WO-2014066613-A2 SPHINGOLIPID METABOLITE MIMETICS ZHEJIANG UNIVERSITY (CN) 2014-05-01 WO disclosed
EP-0216832-B1 NOVEL INSULIN DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES NOVO NORDISK A/S (DK) 1990-08-29 EP disclosed
EP-0216832-A1 NOVEL INSULIN DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES. NORDISK GENTOFTE (DK) 1987-04-08 EP disclosed
WO-1986005496-A1 NOVEL INSULIN DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES NORDISK GENTOFTE A/S (DK) 1986-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031892-A1 SPHINGOLIPID METABOLITE MIMETICS BID, BAD, S1PR1 DPP7 3498/4885RRM1 706/4885GNAI3 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.